SCHEMBL2647600

SCHEMBL2647600

CCCC=Cc1c(C(C)C)nc(C(C)C)c(CO)c1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GCGR P47871 20/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2647597 1.00 GCGR (0.50) GCGR
SCHEMBL2649231 0.89 GCGR (0.57) GCGR
SCHEMBL2648795 0.89 GCGR (0.57) GCGR
SCHEMBL2647256 0.88 GCGR (0.61) GCGR
SCHEMBL2647258 0.88 GCGR (0.61) GCGR
SCHEMBL2647736 0.86 GCGR (0.48) GCGR
SCHEMBL2647287 0.86 GCGR (0.48) GCGR
SCHEMBL2647639 0.85 GCGR (0.63) GCGR
SCHEMBL2647643 0.85 GCGR (0.63) GCGR
SCHEMBL2647858 0.84 GCGR (0.61) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed